Table of Content

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines


2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation


3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past
Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution


4. EXECUTIVE SUMMARY


5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Genome Editing
5.2.1. Evolution of Genome Editing
5.2.2. Genome Editing Technologies
5.2.2.1. CRISPR - Cas System
5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
5.2.2.3. Zinc Finger Nucleases (ZFNs)
5.2.2.4. Meganucleases / Homing Endonucleases

5.3. Applications of Genome Editing Technologies
5.4. Other Emerging Technologies
5.5. Concluding Remarks


6. TECHNOLOGY LANDSCAPE
6.1. Chapter Overview
6.2. Genome Editing: Technology Landscape
6.2.1. Analysis by Type of Gene Editing Technique
6.2.2. Analysis by Gene Editing Approach
6.2.3. Analysis by Type of Gene Delivery Method
6.2.4. Analysis by Type of Gene Delivery Modality
6.2.5. Analysis by Highest Phase of Drug Development Supported
6.2.6. Analysis by Therapeutic Area
6.2.7. Analysis by Application Area

6.3. Genome Editing: Technology Developer Landscape
6.3.1. Analysis by Year of Establishment

6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Operational Model
6.3.5. Most Active Players: Distribution by Number of Technologies


7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Technology Competitiveness Analysis
7.4.1. Genome Editing Technologies Offered by Players based in North America
7.4.2. Genome Editing Technologies Offered by Players based in Europe
7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America


8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Arcturus Therapeutics
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Technology Portfolio
8.2.4. Recent Developments and Future Outlook

8.3. Beam Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Technology Portfolio
8.3.4. Recent Developments and Future Outlook

8.4. Caribou Biosciences
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Technology Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. Century Therapeutics
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Technology Portfolio
8.5.4. Recent Developments and Future Outlook

8.6. CRISPR Therapeutics
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Technology Portfolio
8.6.4. Recent Developments and Future Outlook

8.7. Editas Medicine
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Technology Portfolio
8.7.4. Recent Developments and Future Outlook

8.8. Graphite Bio
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Recent Developments and Future Outlook

8.9. Intellia Therapeutics
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Technology Portfolio
8.9.4. Recent Developments and Future Outlook

8.10. Prime Medicine
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Recent Developments and Future Outlook

8.11. Vor Biopharma
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Recent Developments and Future Outlook

8.12. Other Leading Players
8.12.1. Avectas
8.12.2. Bio-Sourcing
8.12.3. Edigene
8.12.4. Flash Therapeutics
8.12.5. Fortgen
8.12.6. G+FLAS Life Sciences
8.12.7. Ntrans Technologies
8.12.8. OXGENE
8.12.9. Revvity (formerly known as Horizon Discovery)
8.12.10. TargetGene Biotechnologies
8.12.11. ZeClinics


9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Genome Editing Technologies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.7.1. Local and International Agreements
9.3.7.2. Intercontinental and Intracontinental Agreements


10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Editing Domain: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Type of Patent and Publication Year
10.3.3. Analysis by Geography
10.3.4. Analysis by CPC Symbols
10.3.5. Leading Industry Players: Analysis by Number of Patents

10.4. Genome Editing Domain: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Leading Industry Players

10.5. Patent Valuation Analysis

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Genome Editing Domain: Funding and Investment Analysis
11.3.1. Analysis by Year of Investment
11.3.1.1. Cumulative Year-wise Trend of Funding Instances
11.3.1.2. Cumulative Year-wise Trend of Amount Invested

11.3.2. Analysis by Type of Funding
11.3.2.1. Analysis of Funding Instances
11.3.2.2. Analysis of Amount Invested
11.3.3. Analysis by Year and Type of Funding
11.3.4. Analysis by Geography
11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
11.3.6. Leading Investors: Analysis by Number of Funding Instances

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion

13. GENOME EDITING TECHNOLOGIES MARKET
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
13.3.1. Scenario Analysis

13.4. Key Market Segmentations
13.5. Dynamic Dashboard

14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
14.4. TALENs: Forecasted Estimates (2023-2035)
14.5. Meganucleases: Forecasted Estimates (2023-2035)
14.6. ZFNs: Forecasted Estimates (2023-2035)
14.7. Other Techniques: Forecasted Estimates (2023-2035)
14.8. Data Triangulation
14.8.1. Insights from Primary Research
14.8.2. Insights from Secondary Research
14.8.3. Insights from In-house Repository

15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cell Therapies: Forecasted Estimates (2023-2035)
15.4. Gene Therapies: Forecasted Estimates (2023-2035)
15.5. Other Therapies: Forecasted Estimates (2023-2035)
15.6. Data Triangulation
15.6.1. Insights from Primary Research
15.6.2. Insights from Secondary Research
15.6.3. Insights from In-house Repository

16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
16.5. Data Triangulation
16.5.1. Insights from Primary Research
16.5.2. Insights from Secondary Research
16.5.3. Insights from In-house Repository


17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.5. Data Triangulation
17.5.1. Insights from Primary Research
17.5.2. Insights from Secondary Research
17.5.3. Insights from In-house Repository


18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Viral Vectors: Forecasted Estimates (2023-2035)
18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
18.5. Data Triangulation
18.5.1. Insights from Primary Research
18.5.2. Insights from Secondary Research
18.5.3. Insights from In-house Repository


19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
19.4. Diagnostics: Forecasted Estimates (2023-2035)
19.5. Data Triangulation
19.5.1. Insights from Primary Research
19.5.2. Insights from Secondary Research
19.5.3. Insights from In-house Repository


20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
20.5. Data Triangulation
20.5.1. Insights from Primary Research
20.5.2. Insights from Secondary Research
20.5.3. Insights from In-house Repository

21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Forecasted Estimates (2023-2035)
21.4. Europe: Forecasted Estimates (2023-2035)
21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
21.6. Data Triangulation
21.6.1. Insights from Primary Research
21.6.2. Insights from Secondary Research
21.6.3. Insights from In-house Repository

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Milestone Payments: Forecasted Estimates (2023-2035)
22.4. Upfront Payments: Forecasted Estimates (2023-2035)
22.5. Data Triangulation
22.5.1. Insights from Primary Research
22.5.2. Insights from Secondary Research
22.5.3. Insights from In-house Repository

23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS
23.1. Chapter Overview
23.2. Leading Industry Players

24. CONCLUSION

25. EXECUTIVE INSIGHTS

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS